0.2857
price down icon1.72%   -0.005
after-market Dopo l'orario di chiusura: .28 -0.0057 -2.00%
loading
Precedente Chiudi:
$0.2907
Aprire:
$0.2886
Volume 24 ore:
607.96K
Relative Volume:
0.29
Capitalizzazione di mercato:
$25.53M
Reddito:
-
Utile/perdita netta:
$-166.14M
Rapporto P/E:
-0.1488
EPS:
-1.92
Flusso di cassa netto:
$-139.92M
1 W Prestazione:
-8.63%
1M Prestazione:
-74.26%
6M Prestazione:
-61.77%
1 anno Prestazione:
-77.85%
Intervallo 1D:
Value
$0.2812
$0.2931
Intervallo di 1 settimana:
Value
$0.2812
$0.3253
Portata 52W:
Value
$0.228
$1.69

Allakos Inc Stock (ALLK) Company Profile

Name
Nome
Allakos Inc
Name
Telefono
650-597-5002
Name
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Name
Dipendente
131
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
ALLK's Discussions on Twitter

Confronta ALLK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALLK
Allakos Inc
0.2857 25.53M 0 -166.14M -139.92M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Allakos Inc Stock (ALLK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-01-17 Downgrade Jefferies Buy → Hold
2024-01-16 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-12-18 Aggiornamento William Blair Mkt Perform → Outperform
2023-12-08 Ripresa Jefferies Buy
2023-09-27 Iniziato JMP Securities Mkt Outperform
2023-05-12 Aggiornamento Jefferies Hold → Buy
2023-03-07 Iniziato Piper Sandler Overweight
2022-09-12 Downgrade SMBC Nikko Neutral → Underperform
2021-12-22 Downgrade BofA Securities Buy → Underperform
2021-12-22 Downgrade Cowen Outperform → Market Perform
2021-12-22 Downgrade Jefferies Buy → Hold
2021-12-22 Downgrade SVB Leerink Outperform → Mkt Perform
2021-12-22 Downgrade William Blair Outperform → Mkt Perform
2021-08-26 Iniziato Morgan Stanley Equal-Weight
2021-07-15 Iniziato Cowen Outperform
2021-05-18 Iniziato H.C. Wainwright Buy
2021-02-24 Iniziato Cantor Fitzgerald Overweight
2021-01-15 Iniziato BofA Securities Buy
2020-12-21 Iniziato SVB Leerink Outperform
2020-02-27 Iniziato Barclays Underweight
2020-02-04 Ripresa Goldman Neutral
2018-08-13 Iniziato Goldman Neutral
2018-08-13 Iniziato Jefferies Buy
2018-08-13 Iniziato William Blair Outperform
Mostra tutto

Allakos Inc Borsa (ALLK) Ultime notizie

pulisher
Feb 12, 2025

Lee joins Lycia as CMO - BioCentury

Feb 12, 2025
pulisher
Feb 11, 2025

It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News

Feb 11, 2025
pulisher
Feb 10, 2025

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News

Feb 10, 2025
pulisher
Feb 10, 2025

Introducing Our Rant Against Allakos Inc - US Post News

Feb 10, 2025
pulisher
Feb 08, 2025

FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel

Feb 07, 2025
pulisher
Feb 06, 2025

Evaluating Allakos: Strategic Review, NOL Potential, and Kevin Tang's Activist Stake Amidst Biopharma Challenges - Smartkarma

Feb 06, 2025
pulisher
Feb 05, 2025

What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail

Feb 05, 2025
pulisher
Feb 05, 2025

Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR

Feb 05, 2025
pulisher
Feb 05, 2025

Such Is The Power Of Allakos Inc (NASDAQ: ALLK) - Stocks Register

Feb 05, 2025
pulisher
Feb 04, 2025

Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle

Feb 04, 2025
pulisher
Feb 04, 2025

Allakos stock tanks after company announces mass layoffs - MSN

Feb 04, 2025
pulisher
Feb 03, 2025

TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

The time has not yet come to remove your chips from the table: Allakos Inc (ALLK) - SETE News

Feb 03, 2025
pulisher
Feb 03, 2025

Allakos stock plunges to 52-week low of $0.23 amid steep annual decline - Investing.com

Feb 03, 2025
pulisher
Jan 31, 2025

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga

Jan 31, 2025
pulisher
Jan 31, 2025

Allakos stock tumbles following AK006 trial discontinuation - MSN

Jan 31, 2025
pulisher
Jan 30, 2025

Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE

Jan 30, 2025
pulisher
Jan 30, 2025

Allakos plunges 75% on phase 1 data for urticaria asset - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World

Jan 30, 2025
pulisher
Jan 30, 2025

Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive

Jan 29, 2025
pulisher
Jan 28, 2025

Allakos to cease AK006 development after trial setback - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena

Jan 28, 2025
pulisher
Jan 28, 2025

Bay Area biotech firm Allakos suddenly on brink of collapse after trial flops - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Allakos stock hits 52-week low at $0.3 amid market challenges - Investing.com Canada

Jan 28, 2025
pulisher
Jan 28, 2025

Allakos shares fall as Jefferies cuts price target to $0.40 By Investing.com - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 28, 2025

Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter

Jan 28, 2025
pulisher
Jan 28, 2025

Allakos shares fall as Jefferies cuts price target to $0.40 - MSN

Jan 28, 2025
pulisher
Jan 27, 2025

Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals

Jan 27, 2025
pulisher
Jan 27, 2025

Bay Area biotech firm suddenly on brink of collapse after trial flops - SFGATE

Jan 27, 2025
pulisher
Jan 27, 2025

Allakos Restructures Amid AK006 Program Discontinuation - TipRanks

Jan 27, 2025
pulisher
Jan 27, 2025

S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Stock market news: Planet Image International surged by 160.47% while Allakos is still declining by 80.30% during mid day trading - Business Upturn

Jan 27, 2025
pulisher
Jan 27, 2025

Allakos Inc. (ALLK) PT Lowered to $0.40 at Jefferies - StreetInsider.com

Jan 27, 2025
pulisher
Jan 27, 2025

Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch

Jan 27, 2025
pulisher
Jan 27, 2025

Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn

Jan 27, 2025
pulisher
Jan 27, 2025

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga

Jan 27, 2025

Allakos Inc Azioni (ALLK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
Capitalizzazione:     |  Volume (24 ore):